FGF16 has been reported to be preferentially expressed in the adult rat heart. We have investigated the expression of FGF16 in the perinatal and postnatal heart and its functional significance in neonatal rat cardiac myocytes. FGF16 mRNA accumulation was observed by quantitative RT-PCR between neonatal days 1 and 7, with this increased expression persisting into adulthood. FGF2 has been shown to increase neonatal rat cardiac myocyte proliferative potential via protein kinase C (PKC) activation. Gene array analysis revealed that FGF16 inhibited the upregulation by FGF2 of cell cycle promoting genes including cyclin F and Ki67.
Introduction
FGF16, a member of the fibroblast growth factor family, is a 207 amino acid protein containing a core region of 120 amino acids that binds heparin and the FGF receptor (33). It shares 75% and 62% amino acid sequence similarity with its closest relatives FGF9 and FGF20, respectively (26, 32). FGF16 is highly conserved between species and has been cloned from human, rat, mouse, chicken and zebrafish (30). FGF16 was originally characterized in the rat and shown to be expressed preferentially in brown adipose tissue in the embryo (26) and/or FGFR2; however, FGF16 appears to be part of the FGF signaling network acting downstream of Wnt/ -catenin signaling that is required for expansion of anterior heart field progenitor cells (8). Beyond this, however, no functional studies of FGF16, especially its role in postnatal heart, have been presented.
In the rat, FGF16 expression in the late embryo is found predominantly in brown adipose tissue, with a faint signal in the heart. By contrast, in the adult, RNA was detected preferentially in the heart by RNA blotting with only a faint signal in brown adipose tissue (26). With the exception of this intriguing pattern of expression there are no reports as to: (i) which cardiac cell types (myocytes versus non-myocytes) are responsible for production of FGF16 in the postnatal heart, (ii) when expression occurs (perinatal versus adult), (iii) whether the protein is released, 7 limpet hemocyanin (44) and purified by Quality Controlled Biochemicals Inc. (QCB, Hopkinton, MA).
Quantitative (real time) RT-PCR-based Gene Array Assay
To analyze cell-cycle gene regulation, a commercially available targeted cDNA array of 84 cell-cycle regulatory genes, 5 housekeeping genes, as well as RNA quality control, RT and PCR efficiency controls (Cell Cycle PCR Array, SuperArray Bioscience Corporation, Frederick, MD)
were used on a Bio-Rad iCycler according to the instructions of the manufacturer.
Complementary DNA was synthesized using SuperArray RT First Strand Kit. The baseline and threshold values for the real time PCR were defined manually and were kept the same across the PCR Array. Only results without genomic DNA contamination and no RT inhibition were calculated. Data were generated from three independent cardiac myocyte preparations (n=3) as described in and analyzed with the Excel-based PCR Array Data Analysis Template provided by the manufacturer. Details of the mathematical analysis are given in the legend of Table 1 .
Ki67 Labeling Index Assay
Cells were fixed using 1% paraformaldehyde in phosphate-buffered saline (PBS) at 4 C for 15 min. Primary antibodies (Ki67 [Vector Laboratories, Burlington, ON], 1:1000; -actinin [Sigma-Aldrich], 1:500) were applied in PBS with 1% bovine serum albumin (BSA) overnight at 4 C, followed by secondary antibodies (FITC or Texas Red, conjugated, 1:100 [Jackson Laboratory, Bar Harbour, ME]) at room temperature for 1.5 hours, then Hoechst-33342 counter staining (Calbiochem-Behring, San Diego CA) and mounting on slides. Cells were counted using a confocal microscope (12-15 fields per slide) to determine the proportion of -actinin positive cells that also stained for Ki67 or labeling index (LI).
Receptor Binding Assay
Isolated cardiac myocytes or H9c2 myoblasts (wild type or stably transfected with FGFR1 (42)) were plated onto 96-well plates at a density of 3 x 10 4 cells per well. After 24 hours the cells were washed twice with binding buffer (300 mM sucrose, 100 mM NaCl, 50 mM Hepes, 1.2 mM CaCl 2 , 1.2 mM MgCl 2 , and 0.5% BSA). Iodinated FGF2 (60 pM, corresponding to 1ng/ml) was added to each well along with cold competitor (FGF2 or FGF16) and the cells were incubated for 1 hour at 37 C, then washed with binding buffer (2x) and 2 M NaCl, 20 mM
Hepes. Cells were lysed on ice in two changes of 0.5 M NaOH and 0.1% Triton X-100 for 10 min each, and transferred to glass vials. Scintillation fluid was added and counts were read after 1 hour at room temperature. The counting efficiency (cpm/dpm) was calculated to correct for quenching (15, 48) and results were interpreted with the assumption that there was no preferential internalization of any receptor under these conditions (i.e., that all receptors are represented in the assay).
Signal Transduction
For assessment of phosphorylated mitogen activated protein kinase (MAPK), cells were washed (2x) with ice cold PBS, and flash frozen with liquid nitrogen. For processing, 0.5 ml of lysis buffer (50 mM Tris HCl pH 6.8, 10 mM NaF, 2% SDS, 25 mM -glycerophosphate, 1mM
Na 3 O 4 V, 1mM EDTA, 1mM EGTA and protease inhibitor) was added. Cells were removed with a rubber policeman, sonicated briefly and centrifuged to remove insoluble material. MAPK phosphorylation/activation in the supernatant was assessed by protein immunoblotting as decribed above using a phosphospecific MAPK sampler kit (Cell Signaling Technology, Boston, MA).
For assessment of protein kinase C (PKC) levels, cells were fractionated into cytosolic and membrane components following growth factor stimulation (1 ng/ml FGF2, 100 ng/ml FGF16 and/or 10 nM insulin-like growth factor 1 (IGF1)); IGF1 was a generous gift from Dr. Suresh Mishra (University of Manitoba). Cells were mechanically lysed (23G needle) in homogenization buffer, spun to remove nuclei, and after further centrifugation (186,000g for 2 hours) the supernatant was collected as the cytosolic fraction. The pellet was resuspended in PBS with 0.5% Triton X-100 and protease inhibitors, homogenized and sonicated briefly. Following incubation on ice for 30 min and further centrifugation (154,000g for 30 min), the supernatant was collected and assayed as the membrane fraction. PKC levels in fractions were assessed by SDS-PAGE and protein immunoblotting as described above. Antibodies against PKC and PKC were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Statistical Analysis
Statistical analysis was performed using Instat® by GraphPad. Multiple column comparisons were achieved using one-way or, in the case of the PCR gene array data, 
Results

RNA expression profile for FGF16 in perinatal and postnatal heart
The temporal expression of FGF16 was detected by real time RT-PCR from total RNA of rat heart at late embryonic stages (E19, E20) as well as postnatal days 1, 7, and 14, and 8 weeks (adult). In contrast to the very low FGF16 expression at late embryonic stages, a marked increase in FGF16 mRNA accumulation was observed to begin between postnatal day 1 and 7 then continuing to increase into adulthood (Fig. 1 Supplementary Material for a complete list of genes and their functional categories). Neonatal rat cardiac myocytes in culture were treated with FGF2 (1ng/ml) for a dual purpose: (i) to act as a positive control for cell cycle entry (36), and (ii) as a means to test the effect of FGF16 against a background of enhanced proliferative potential. Two criteria were used to define an 'effect': the average response from three independent experiments involving separate myocyte cultures must be (i) increased or decreased by at least two fold, and (ii) statistically significant (treatment versus control) after paired analysis of variance (p<0.05). As shown in Table 1 , FGF2 (1ng/ml) treatment upregulated several genes that promote the cell cycle, including cyclin F (2, 5, 17) and Ki67 (40) . FGF16 alone, even at a high concentration (100 ng/ml) had no marked effect on any cell cycle gene compared to control. However, at this concentration FGF16 abrogated the FGF2-induced increase of cyclin-F and Ki67 expression. Furthermore, the CDK4/6 inhibitor gene Arf/INK4A (31, 37) was upregulated by the combined effect of FGF2 and FGF16.
FGF16 interferes with FGF2-induced Ki67 labeling in neonatal cardiac myocytes.
Ki67 is present during all active phases of the cell cycle, but not in quiescent (G0) cells (40), making it an indicator of cell cycle entry. To validate the gene array at the protein level, Ki67 expression was assessed through immunodetection in -actinin positive cells (Fig. 3A) . The Ki67 labeling index (LI) is defined as the fraction (percentage) of -actinin-positive cells counted in a microscopic field that also stained for Ki67. The absolute value for the LI in untreated cardiac myocytes was 1.68 ± 0.24% (n=67 fields). Consistent with the gene array assay, FGF16 treatment alone had no effect on the Ki67 labeling index (LI). However, FGF16 decreased FGF2 induced Ki67 LI significantly (Fig. 3B ).
Inhibition of p38 MAPK was shown to potentiate or enhance proliferation of postnatal cardiac myocytes following treatment with FGF1 (13), thereby implicating elevated p38 MAPK in the lack of proliferative potential for cardiac myocytes. To test whether (i) FGF2 can substitute for FGF1, and (ii) p38 MAPK mediates the interference of FGF16 with FGF2-induced cardiac myocyte growth, cells were treated with FGF2 with p38 inhibitor (SB203580, 10 µM) (13), with or without FGF16. The Ki67 LI was determined as described above. The combination of FGF2 with p38 inhibition increased the Ki67 LI significantly over FGF2 or inhibitor treatment alone ( Fig. 3B ). However, when FGF16 was added to cultures treated with FGF2 and p38
inhibitor there was a significant (but not complete) loss of proliferative potential, indicated by an decrease in the Ki67 LI (Fig. 3B ).
FGF16 can compete with FGF2 for binding to cell surface FGF receptors
Proliferation of cardiac myocytes by FGF2 has been linked to signaling via the cell surface receptor FGFR1 (41, 45) . We have shown previously that overexpression of FGFR1 increased cell division both in rat myoblast H9c2 cells stably transfected with FGFR1 (42) competed in a specific manner (Fig. 4B ). The possibility of receptor internalization is acknowledged, but does not change the observation that both cold FGF2 and cold FGF16
competed with 125 I-FGF2 for binding sites in a dose-dependent manner.
FGF16 interferes with protein kinase C activation by FGF2
FGF2 triggers multiple signaling pathways in cardiac myocytes including both MAPK and protein kinase C (PKC) (10). To investigate the effect of FGF16 on MAPK activation, protein immunoblotting was performed for both total and phosphorylated p38 MAPK, ERK1/2 and JNK/SAPK expression after treatment with FGF2 or FGF16, alone or in combination. No change in total p38 levels was observed with any treatment (Fig. 5A) . A time course of treatment with 1 ng/ml FGF2 indicated that 5 minutes was a point of maximal p38 phosphorylation (Fig. 5A ). At this time point, FGF16 had a minimal but detectable effect on p38 phosphorylation compared to control, but no further effect was evident when used in combination with FGF2, comparing to FGF2 alone (Fig. 5A ). FGF2 had a similar effect on other MAPKs, including ERK1/2, and JNK/SAPK, but FGF16 had no effect, either on its own or on the effect of FGF2 (data not shown).
FGF2 is known to stimulate PKC isoforms, including the conventional (calcium-dependent) PKC (43) and the novel (calcium-independent) PKC (12). The levels of PKC and PKC in the cytosolic versus membrane fraction were detected after FGF2/FGF16 treatment by SDS-PAGE and protein immunoblotting. The 80 kDa PKC and 90 kDa PKC bands were detected in the cytosolic fraction but, although present at relatively high levels, there was no obvious change by FGF treatments (not shown). By contrast, FGF2 but not FGF16 increased PKC and PKC levels in the membrane fraction (Fig. 5B) . However, when 100 ng/ml FGF16 was added in combination with 1 ng/ml FGF2, the observed increase was lost (Fig. 5B ). In addition, we found that treatment with FGF16 at lower concentrations (10 ng/ml, and in 2 of 3 replicates using 1 ng/ml) also resulted in significant inhibition of FGF2-induced PKC activation, suggesting a dose-dependent effect of FGF16 (data not shown).
To test whether the ability of FGF16 to modulate PKC activity was specific to FGF2/FGFR and consistent with receptor competition, IGF1 was used to replace FGF2 for PKC activation (14) . Treatment with 10 nM IGF1 for 2 minutes increased membrane PKC levels (Fig. 5C ).
Combined treatment with FGF16 (100 ng/ml) inhibited the increase in both membrane PKC and PKC levels (Fig. 5C ).
Discussion
The preferential expression of FGF16 in the adult heart appears to be a unique characteristic among members of the FGF family (26). In this study, we provide evidence that FGF16 RNA expression is induced in the early postnatal myocardium and its protein is produced and released from neonatal cardiac myocytes. It is generally accepted that cardiac myocytes lose their ability to divide shortly after birth (27). The mechanism, however, is poorly understood, particularly as Another possible mechanism for FGF16 inhibition of FGF2-stimulated growth was suggested by the negative regulation of cardiac myocyte proliferation by p38 (13). Although a slight effect of FGF16 on its own was observed ( (44) and Fig. 5A ), we did not observe any regulation of cell cycle gene expression by FGF16 itself and were unable to link the inhibitory regulation of FGF16 on FGF2-induced growth to p38 MAPK activation. We found p38
inhibition enhanced the FGF2-induced Ki67 LI; however, it did not abolish the inhibitory effect of FGF16 (Fig. 3) . Consistent with this, immunoblot assays showed that FGF16 did not change FGF2-induced p38 activation (Fig. 5) . The growth response of cardiac myocytes, then, appears to involve a complex array of signaling pathways whose activity is determined not only by the presence of ligands that directly activate them, but also by ligands that may also serve to potentiate (or suppress) the growth response under certain physiological (i.e., developmental) or pathological conditions. Indeed, the suggestion that FGF16 may be a negative regulator for postnatal cardiac growth may translate to potential to interfere with the pressure-induced hypertrophic process mediated by other growth factors (including FGF2). The prospect of an anti-hypertrophic effect of FGF16 is very intriguing, particularly from a clinical point of view.
As systems are employed to further study the function of FGF16 in vivo, this concept will be explored further.
In summary, FGF16 expression increases in the myocardium at birth where this heparinbinding protein has the capacity to be produced and released in a glycosylated form and to modify the signaling environment. The appearance of FGF16 in the postnatal heart correlates with a change in the proliferative potential of cardiac myocytes. A role for FGF16 in this transition is suggested by its ability to interfere with the proliferation potential of neonatal cardiac myocytes through a mechanism involving modulation of PKC activation and an effect on cell cycle-related gene expression. Cultures of neonatal cardiomyocytes were treated with vehicle, FGF2 (1ng/ml), FGF16
(100ng/ml), or FGF2 combined with FGF16, for 24 h, followed by extraction of total RNA. Real 
